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ABSTRACT
Diabetes mellitus (DM) is a common and devastating disease,
affecting up to 19.3millionAmericans. It is the leading cause of
chronic kidney disease (CKD) and end-stage renal disease
(ESRD) in the United States. Diabetic patients with ESRD
have a high incidence of cardiovascular disease and death. For
those kidney transplant patientswith no history ofDMprior to
transplantation, the development of new onset diabetes after
transplantation (NODAT) also poses a serious threat to both
graft and patient survival. Kidney transplantation is the best
renal replacement option for diabetic ESRDandhas the poten-
tial to halt the progression of cardiovascular diseases. Early
referral for transplant evaluation is essential for pre-emptive or
early kidney transplantation in this cohort of patients. In type 1
DM patients with ESRD, simultaneous pancreas and kidney
transplantation (SPK) should be encouraged; and in patients
facingprolongedwaiting time forSPKtransplantationbutwith
an available living donor, living donor kidney transplantation
followed by pancreas after kidney transplantation (PAK) is a
suitable alternative. Islet transplantation in type 1 diabetics is
deemed experimental by Medicare, and easy access to this
modality remains restricted toqualifiedpatients enrolled in clin-
ical trials or with private insurance. The optimal management
of kidney transplant patientswith pre-existentDMorNODAT
involves amulti-prongedapproachconsistingofpharmacologi-
cal and nonpharmacological intervention to address all poten-
tial cardiovascular risk factors such as glycemic and lipid
control, bloodpressure control,weight loss, and smoking cessa-
tion. Finally, re-transplantation should be recommended in
suitable kidney transplant patients when the kidney allograft
demonstrates continuous andprogressive decline in function.
Diabetes mellitus (DM) affects an estimated 19.3
million American adults with a prevalence of 9.3% (1).
Its incidence continues to increase, particularly in the
developing countries, and it is estimated that by 2025,
300 million people worldwide will be affected by this
condition (2).DM is a strong risk factor for cardiovascu-
lar disease, chronic kidney disease (CKD), and prema-
ture death in the adult population (3–5). In fact, diabetic
kidney disease occurs in 20–40% of patients with DM
and is the leading cause of CKD and end-stage renal dis-
ease (ESRD) in the United States, accounting for nearly
45% of the dialysis patient population (6–8). In patients
with both DM and CKD, the incidence of various car-
diovascular complications and death is much higher
than either condition alone (5,8).
Most diabetic patients will die of cardiovascular
events prior to developing CKD or progressing to
ESRD. For those who develop diabetic nephropathy, as
evidenced by the appearance of microalbuminuria
and decline in glomerular filtration rate (GFR), with
eventual progression to ESRD, kidney transplantation
is the renal replacement therapy of choice. In type 1
diabetics with ESRD, simultaneous pancreas and
kidney (SPK), or pancreas after kidney (PAK) trans-
plantation are feasible options for qualified individuals
whereas islet transplantation remains experimental at
this time (9,10).
In patients without previous history of DM, any form
of solid organ transplantation constitutes a risk factor
for the development of new onset diabetes after trans-
plantation (NODAT) (11). The development of
NODAT portends an additional cardiovascular risk to
transplant patients in general and to kidney transplant
patients in particular (12,13).
Diabetes mellitus, present prior to or developing after
kidney transplantation, represents a unique challenge to
kidney transplant patients. In this review, we will focus
our discussion on kidney transplantation as the treat-
ment for diabetic ESRD patients, the effects of new
onset diabetes after kidney transplantation, and on
pancreas transplantation in type 1DMpatients.
Progression of Diabetic Chronic Kidney Disease
and the Timing of Kidney Transplantation
Historically, 20–40% of diabetic patients develop
diabetic nephropathy over a period of 25 years from the
onset of disease, and 5–15% progress to ESRD (14–16).
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IMPROVING OUTCOMES FOR DIABETIC PATIENTS ON DIALYSIS
Besides genetic risk factors, hypertension, and hypergly-
cemia are the two most important risk factors for the
development and subsequent progression of diabetic
CKD (17–22). Aggressive lowering of blood pressure to
130 ⁄80 mmHg or less with the use of an angiotensin-
converting enzyme inhibitor (ACEI) and ⁄or angiotensin
II receptor blocker (ARB) and strict glucose control,
targeting HbA1c to near normal (<7%), appear to slow
the progression of diabetic CKD (20,21,23,24).
Nevertheless, a portion of patients will experience
progressive decline in renal function and subsequent
ESRD (22). Ultimately, these patients will require life-
sustaining, long-term renal replacement therapy, either
in the form of dialysis or kidney transplantation.
As in any other patient with CKD, the preparation
for renal replacement therapy of diabetic patients
requires focused patient education and timely referral to
the nephrologist, vascular surgeon, and transplant spe-
cialist. Delayed referral for specialized care is common
and results in poor pre-ESRD care, whereas timely refer-
ral improves the likelihood of pre-emptive or early (i.e.,
within the first 2 years of dialysis therapy) kidney trans-
plantation (25–27). The choice of dialysis or kidney
transplantation depends on many factors, including
timely recognition of continued decline in renal function,
resource availability, and patient co-morbidity. In the
United States, the overwhelming majority of incident
diabetic patients with ESRD will be initiated on renal
replacement therapy in the form of hemodialysis, a phe-
nomenon that is not exclusive to diabetic patients (8).
Diabetic CKD patients experience a high incidence of
cardiovascular events and death that is further increased
after they begin dialysis therapy (5,8,28). Kidney trans-
plantation provides a better alternative when compared
with dialysis as far as overall and cardiovascular mortal-
ity is concerned, a benefit that is particularly enjoyed by
both type 1 and 2 diabetics. In a landmark study, Wolfe
et al., examined at a national level the mortality among
ESRD patients wait-listed for a kidney transplant when
compared with that of ESRD patients who received a
deceased donor kidney transplant (29). Kidney trans-
plantation was associated with a significantly lower risk
of death 18 months after transplantation (relative risk,
0.32, 95% CI 0.30, 0.35) with survival benefit clearly
demonstrable 244 days after transplantation. The pro-
jected increase in life expectancy by transplantation was
10 years on average across all kidney transplant
patients; of note, this survival advantage was particu-
larly strong in diabetic ESRD patients, mainly because
of their poorer survival on dialysis. Other investigators
from different parts of the world have shown similar
findings supporting the reproducibility of Wolfe’s find-
ings (30,31). A reduction in cardiovascular risk is the
main reason for the survival advantage conferred by
kidney transplantation (28,32).
The optimal timing for kidney transplantation in a
diabetic patient with advanced CKD and ⁄or ESRD is
largely amatter of availability of a donor kidney. Avoid-
ing dialysis or at least limiting its duration to no more
than 180 days is associated with better post-transplant
outcome and should be strongly recommended (33–35).
Mange et al. showed that living donor kidney transplant
recipients without previous history of dialysis treatment
had a 52% reduction in risk of graft failure within the
first year after transplantation, when compared with
those who were on dialysis at the time of transplantation
(p = 0.002), with further reduction of risk during subse-
quent years following transplantation (82% in second
year and 86% thereafter, respectively, p = 0.001) (33).
Mange further observed that longer duration of dialysis
treatment prior to transplantation was associated with
increased risk for acute rejection within the first
6 months of transplantation.
In a subsequent study, Kasiske et al. demonstrated
similar findings in patients receiving a deceased donor
kidney transplant (25% risk reduction in graft failure for
pre-emptive kidney transplant recipients when com-
paredwith those patients who had initiated dialysis prior
to kidney transplantation) (36). More importantly,
according to those investigators, the pre-emptive kidney
transplantation resulted in improvement of patient sur-
vival (26% and 31% risk reduction in patient death for
deceased and living donor kidney transplant recipients,
respectively). More recently, Becker et al. investigated
the benefit of pre-emptive kidney transplantation in type
1 and 2 diabetic ESRD population (37). The benefit of
pre-emptive transplantation in this patient population
regarding patient and graft survival was only observed
after living donor kidney or SPK transplantation.
Thus, it is important to emphasize the advantage of
pre-emptive living donor kidney transplantation in dia-
betic ESRD patients. Since diabetic patients come to
receive medical attention much earlier than patients
with nondiabetic CKD, early screening for kidney dis-
ease should be part of routine care for diabetic patients
which consists of measurement of both microalbuminu-
ria and serum creatinine (38). Once kidney disease is
detected, periodic and ongoing monitoring of GFR
becomes one of the most important aspects of patient
care with regard to slowing the progression to ESRD
and preparing for pre-emptive living donor kidney
transplantation (27,39).
As more than 86,000 patients with ESRD are cur-
rently waiting for a kidney transplant and a little more
than 13,000 kidney transplants are performed annually
in the United States, the waiting time for a deceased
donor kidney transplant has remained stagnant across
the nation with a median time of three or more years
(40). The avoidance of dialysis or shortening the length
of dialysis is only possible if patients with CKD are
referred to nephrologists and ⁄or transplant centers when
estimated GFR (eGFR) is around 30 ml ⁄min, with the
goal of listing the patient as soon as the eGFR declines
to an average value of 20 ml ⁄min or less, the UNOS
requirement for placement in the renal transplant wait-
ing list in theUnited States.
Under most circumstances, however, pre-emptive
kidney transplantation is more likely to occur with a
living donor as there is no waiting time involved.
Discussion of the benefits of pre-emptive living donor
kidney transplantation, and encouraging appropriate
recipient candidates to search for potential living donors
should be considered as part of a transplant evaluation
process.
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Management of Diabetic ESRD Patients after
Kidney Transplantation
Although kidney transplantation is the superior treat-
ment modality for patients with ESRD, the survival of
kidney transplant patients remains inferior to that of the
general population in part because of the accumulated
cardiovascular burden and CKD vintage (41,42). The
same cardiovascular risk factors that are relevant in the
general population remain relevant in kidney transplant
patients (43,44). In particular, the presence of DM and
cardiovascular disease prior to kidney transplantation
represents the most important predictors for cardiovas-
cular events and all-cause mortality after kidney trans-
plantation (45–47). In a cohort of 933 first-time kidney
transplant patients, Cosio et al., showed that when com-
pared with nondiabetic kidney transplant patients, kid-
ney transplant patients with history of DM had a
significantly higher incidence of post-transplant cardio-
vascular events (25% vs. 7.4%, p < 0.0001), cardiovas-
cular mortality (12% vs. 1.1%, p < 0.0001) and
all-cause mortality (19.3% vs. 6.1%, p < 0.0001) (45).
Aalten et al. from the Netherlands showed similar find-
ings in that pretransplant diabetic nephropathy was
associated with a more than three times higher risk of
having post-transplant cardiovascular events (46). It
appeared that the high cardiovascular burden in DM
patients before kidney transplantation was the driving
force for persistence of elevated cardiovascular events
observed after kidney transplantation.
It is important to point out that the incidence of car-
diovascular events and death is highest in the first
3 months after kidney transplantation (29,44–46,48).
This has been attributed to the fact that prolonged CKD
and ESRD markedly increase cardiovascular risk, and
multiple other comorbid conditions (43,49). Further-
more, despite the improvement in cardiovascular risks
observed in patients following kidney transplantation,
newer transplant-related risk factors such as immuno-
suppressive drugs, and inflammation due to opportunis-
tic infection, particularly cytomegalovirus infection,
perpetuate the high cardiovascular risk status of the
kidney transplant patient population (48,50). The fact
that the majority of kidney transplant patients will have
amild tomoderate degree of CKDmakesmatters worse
(51,52).
The role of immunosuppressive drugs on promoting
cardiovascular risks has been well-documented (53). For
example, the use of steroids, calcineurin inhibitors
(CNIs) such as cyclosporine and tacrolimus, and more
recently sirolimus can all contribute to and exacerbate
hypercholesterolemia and hypertriglyceridemia that are
already highly prevalent in kidney transplant patients
(54–56). Hypertension, another conventional cardiovas-
cular risk factor, is present in over 75% of kidney trans-
plant patients, and its control is influenced negatively by
steroids and CNIs (50,57). Both hyperlipidemia and
hypertension are associated with reduced renal allograft
survival in addition to increased risk for cardiovascular
disease (58,59). For each 10 mmHg incremental rise in
SBP, the risk for death and graft failure increases by
18% and 17%, respectively (59). In diabetic ESRD
patients, glycemic control tends to get worse and difficult
to manage shortly after kidney transplantation. Insulin
requirement may increase and oral hypoglycemic agents
may fail, mostly because of increased insulin resistance
and impaired insulin secretion associated with the use of
steroids andCNIs (60–62).
At the present time, any improvement in cardiovascu-
lar disease risk in diabetic kidney transplant patients
hinges on the appropriatedmanagement of conventional
cardiovascular risk factors. The use of statins, possibly
early after kidney transplantation, to lower LDL choles-
terol has been shown to reduce cardiac death, nonfatal
myocardial infarction, proteinuria, and interstitial
fibrosis in the kidney allograft recipient (63–67). Asmost
statins and CNIs are metabolized through the same
cytochrome P450 system (CP3A4), attention should be
paid to an increased frequency of rhabdomyolysis
because of accumulation of statins in plasma with the
use of CNIs (68). The reduction of LDL cholesterol to
less than 100 mg ⁄dl is generally recommended, but for
diabetic kidney transplant recipients with history of pre-
existent cardiovascular disease, a goal of LDL choles-
terol of less than 70 mg ⁄dlmay be optimal (56,69).
Blood pressure control had to target a goal of
£130 ⁄80 mmHg or £125 ⁄70 mmHg in the setting of
established proteinuria (70). The choice of various anti-
hypertensive agents often depends on the type of
patients and the timing following kidney transplantation
(71). Calcium channel blockers (CCB) are widely used as
first-line therapy, particularly early post-transplantation,
to counteract the vasoconstrictive effects of CNIs
(57). While the use of ACEI and ARB is becoming
more widespread their renal protective role, beyond
decreasing proteinuria, has not been universally docu-
mented in kidney transplant patients (72–74). Glyce-
mic control should target HbA1c of less than 7% and
fasting plasma glucose of 90–130 mg ⁄dl (7,75). The
use of various oral hypoglycemic agents and ⁄or insu-
lin depends on pre-transplant DM history. Referral to
an endocrinologist is highly recommended.
It is important to emphasize that, in addition to the
aforementioned pharmacological interventions to
improve cardiovascular risk factors, lifestyle modifica-
tion including dietary precautions, increasing physical
exercise, weight loss, and smoking cessation should be
strongly recommended, although the adherence to life-
stylemodification is notoriously poor (76–81).
New Onset Diabetes after Kidney
Transplantation
Patients with no history ofDMprior to the transplan-
tation are at risk of developing NODAT. Kasiske et al.
studied 11,659 Medicare beneficiaries of first kidney
transplant recipients and found a cumulative incidence
of NODAT of 9.1%, 16%, and 24% at 3, 12, and
24 months after transplantation, respectively (11).
Woodard et al. compared the incidence of NODAT
between transplanted kidney patients and wait-listed
nondiabetic ESRD kidney transplant candidates. They
found that the cumulative incidence of NODAT more
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than doubled when compared with pretransplantation
level (82). In both studies, the risk of NODATwas high-
est in the first year after transplantation, although the
risk remains elevated through the late post-transplant
period (83). The development of NODAT increases the
risk for cardiovascular events and the mortality follow-
ing kidney transplantation (Fig. 1A,B) (12,13).
In addition to overt NODAT, kidney transplant
recipients are at a greater risk for insulin resistance with
a significantly high proportion of them having impaired
glucose tolerance (IGT) and ⁄or impaired fasting glucose
(IFG), compared to the general population (84–86).
IFG, a potential precursor of overt DM, occurs in about
26% of the US adult population and is associated with
other cardiovascular risk factors (1,87,88). It has been
suggested that IFG is a surrogate marker of insulin
resistance that is ultimately responsible for the adverse
cardiovascular outcome (89).
Besides traditional risk factors involved in pretrans-
plant diabetes mellitus, the use of immunosuppressive
drugs plays a major role in the genesis of NODAT and
IGT (11,90). Steroids cause insulin resistance, CNIs
impair secretion of insulin, and sirolimus decreases
insulin sensitivity (60–62,91). More recently, the use
of steroid-free immunosuppression appears to have
decreased the risk of NODAT (Fig. 2) (92–95). Never-
theless, modification of immunosuppression purely for
the purpose of decreasing the risk of NODAT has to be
balanced with the need of preventing graft rejection, as
acute rejection may increase in steroid-free immuno-
suppression and has a stronger deleterious effect on graft
survival (93,96).
The early detection of impaired glucose metabolism
and NODAT in kidney transplant patients has been
advocated by many investigators (86,97). Whether early
detection leads to long-term graft and patient survival
remains to be determined. Therapeutic intervention for
patients who developedNODAT should include lifestyle
modification, the use of oral hypoglycemic agents
and ⁄or insulin (75).
Pancreas Transplantation in Diabetic ESRD
Patients
For type 1 and, rarely, type 2 diabetic patients, pan-
creas transplantation is also an option (98). Pancreas
transplantation can be performed either at the same time
of kidney transplantation (SPK transplantation) or after
kidney transplantation (PAK transplantation). Pancreas
transplantation can also be performed in type 1 DM
patients without evidence of nephropathy (pancreas
transplantation alone), and islet transplantation can be
carried out before or after kidney transplantation. These
last two subjects are beyond the scope of this review and
will not be discussed further.
In a registry data analysis, Ojo et al. compared patient
survival between comparable type 1 diabetic ESRD
patients who received SPK, and living or deceased donor
kidney transplant alone. Patients with SPK had better
survival when compared with deceased but not to living
donor kidney transplant alone recipients (99). When
those patients who received SPK or kidney alone using
contralateral kidneys from the same deceased donor
were compared, the survival advantage of SPK was no
longer observed (100).
In studies where SPK transplantation has resulted in
long-term improvement of patient survival, pancreas
A
B
Fig. 1. Kaplan–Meier estimates of cardiac event-free survival
(A) and patient survival (B) in renal transplant recipients according
to the presence or absence of pre-existent diabetes, new onset
diabetes. Adapted from Hjelmesaeth et al. with permission (13).
Fig. 2. Cumulative incidence of new onset diabetes in a national
cohort of kidney transplant recipients discharged on steroid-free
immunosuppressive regimens (96).
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allograft survival played an important role (101,102). In
a recent study of more than 3000 SPK patients followed
for a maximum of 18 years, Morath et al., showed supe-
rior patient survival for SPK patients when compared
with living donor kidney transplant alone patients
beyond the 10th year after transplantation (hazard ratio
0.55, p = 0.005) (103). For patients who undergo PAK
transplantation, the patient survival may be worse than
those patients treated with conventional therapy,
although one recent study showed otherwise (104,105).
On the contrary, successful pancreas transplantation
does improve metabolic control and the cardiovascular
risk profile, and can potentially reverse diabetic end
organ damage as demonstrated by many investigators
(106–110). In addition, the improvement in quality of life
(QOL) will play an important role in determining the
utility of pancreas transplantation. Several QOL studies
have shown thatwhen pancreas transplantationwas suc-
cessful, patients reported improvement in QOL when
compared with type 1 diabetics who received a kidney
transplant alone (111,112).
It is therefore safe to say that pancreas transplantation
is a suitable option for type 1 diabetic ESRD patients.
SPK transplantation should be discussed as one of the
treatment options for type 1 diabetic ESRD patients,
and equally encouraged as living donor kidney trans-
plantation to qualified candidates.
Management of Failing Graft and
Retransplantation in Diabetic Patients
Kidney graft failure represents a serious challenge to
the transplant physicians as the process itself incurs an
additional risk for patient survival. Rao et al. showed
that the mortality risk increased significantly after kid-
ney graft failure when compared with first-time kidney
transplant candidates on the waiting list (hazard ratio
1.78, p < 0.0001), and mortality was greater among
patients with DM than those without DM (hazard ratio
1.93 vs. 1.69) (113). Similar findings were present in type
1 DM kidney transplant patients who lost kidney graft
and returned on dialysis (114).
These data suggest that it is advisable for diabetic kid-
ney transplant patients with failing kidney grafts to be
evaluated for retransplantation before they actually
return to dialysis. Nonetheless, retransplantation does
represent a significant challenge because of the increased
risk of subsequent graft failure that has been docu-
mented (115,116). Additional studies are needed to
define the best timing for a repeat transplantation, and
the optimalmanagement of diabetic patients undergoing
repeat kidney transplantation.
Conclusion
Although kidney transplantation represents the best
opportunity for diabetic patients with ESRD, improving
their survival after kidney transplantation remains a
substantial challenge. As diabetic patients, on dialysis or
after kidney transplantation, continue to carry a huge
cardiovascular burden, only approaches that address
multiple risks will have the potential to make an impact
on outcomes. Neither improvement in glycemic control,
improvement in hypertension and hyperlipidemia, pre-
vention of weight gain, nor smoking cessation alone is
likely going to change the outcome, but the combination
of all of themwill potentially help our patients to achieve
a longer survival.
Since clinical trials assessing the cardiovascular benefit
of particular therapeutic interventions in kidney trans-
plant patients are scarce to nonexistent, future research
in this area will be critical to guiding our approach.Until
then, physiciansmust extrapolate the best evidence prac-
tice obtained from the general population to the diabetic
kidney transplant population.
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